top of page

Bruce Levine on UPenn's Center for Cellular Immunotherapies and his thoughts regarding FDA's recent CAR-T guidance

Dr. Levine highlights work being done at UPenn including a 3-day CAR with IL-18 and a dual CAR targeting GBM. Plus, his reaction to the secondary malignancy topic that has been in the news.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page